DOCSLIB.ORG

Pancreatic Polypeptide Is Increased in Patients with Advanced Malignant Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pancreatic Polypeptide Is Increased in Patients with Advanced Malignant Disease ANTICANCER RESEARCH 24: 2515-2518 (2004) Pancreatic Polypeptide is Increased in Patients with Advanced Malignant Disease AUDHILD HJALMARSEN1, ROY M. BREMNES2, ULF AASEBØ1, ROLF JORDE3 Divisions of 1Pulmonary Medicine and 3Endocrinology, Department of Medicine and 2Department of Oncology, University Hospital of Northern Norway, N-9038 Tromsø, Norway Abstract. Background: Augmented secretion of pancreatic dysfunction in patients with severe chronic obstructive polypeptide (PP) has been demonstrated in patients with severe pulmonary disease as well as in patients with systemic lupus systemic diseases or endocrine tumors. The aim of this study was to erythematosus (3,4). PP secretion has been localized to a evaluate PP and autonomic neuropathy in patients with advanced specific population of human islet cells and has also been malignant disease. Materials and Methods: Basal PP assessments shown to be produced and released by pancreatic endocrine and five cardiovascular tests for autonomic function were used. tumors (5). PP-producing tumors are mostly located in the Twenty patients, including 11 patients with lung cancer (69 yrs±11, pancreas and may present as three pathological lesions: pure mean±SD) and 10 healthy age-matched controls, were studied. PP-omas, mixed tumors with minor PP cell population and Results: PP levels were significantly higher in the patients than in PP-cell hyperplasia. Numerous types of extrapancreatic the controls (pmol/L 107.0±111.4 versus 28.2±13.4, p<0.05). In endocrine tumors are able to synthesize and secrete PP (5,6). the parasympathetical tests, the patients showed significantly The aim of this study was to assess serum PP concentrations decreased heart rate response to the Valsalva manoeuvre (ratio in patients with advanced malignant disease including lung 1.20±0.19 versus 1.46±0.23, p<0.005). Also, in the sympathetical cancer. We also assessed autonomic neuropathy as an indirect tests, the blood pressure response to standing up was significantly measure of vagal stimulation (7-10). Since all these test results decreased (mmHg –3.84±17.53 versus 10.80±8.89, p<0.05). The may be age-dependent, an age-matched control group was heart rate response to standing up and deep breathing, as well as included (6,11). the blood pressure response to sustained handgrip, did not differ significantly between the groups. In spite of the apparent Materials and Methods autonomic dysfunction among cancer patients with advanced malignant disease, PP levels were significantly higher in these Patients. Twenty patients with advanced malignant disease including patients when compared with healthy controls. Conclusion: PP 11 patients with lung cancer, were enrolled in the study. The mean levels were significantly higher in patients with advanced cancer age was 69 years (range 38-82) and 65% of the patients were male. The cancer diagnosis was based on histological examination and than controls, regardless of autonomic dysfunction in the cancer disease extension was confirmed by CT-scan and/or whole body patients. This finding supports the hypothesis that PP may, in some scintigraphy. The tests were performed before the start of chemo- or cancer patients, be a marker of advanced malignant disease. radiotherapy. Ten age-matched healthy subjects served as controls. Informed consent was obtained from all the subjects. The study was Previous studies have shown that pancreatic polypeptide (PP) approved by the regional Ethics Committee. is reduced in diabetic patients with autonomic neuropathy (1,2). PP consequently has been considered a useful marker Methods. The Performance Status was assessed according to a 5-point scale by WHO (12). of vagal efferent integrity (1,2). However, other studies have shown augmented PP secretion regardless of autonomic Basal pancreatic polypeptide. Prior to cytotoxic treatment, fasting blood samples for basal serum PP were collected, stored and analyzed as previously described (13). Correspondence to: A. Hjalmarsen, Department of Medicine, Tumor markers. Fasting blood samples for carcinoembryonal antigen University Hospital of Northern Norway, N-9038 Tromsø, (CEA), neuron-specific enolase (NSE) and prostate-specific antigen Norway. Tel: +47 776 26000, Fax: +47 776 2686, e-mail: (PSA) were analyzed prior to treatment start. [email protected] Cardiovascular tests. Five cardiovascular tests of autonomic function Key Words: Malignant disease, cardiovascular tests, pancreatic were employed as previously described (7,8,14,15) in the following polypeptide. order: heart rate response to Valsalva manoeuvre; heart rate 0250-7005/2004 $2.00+.40 2515 ANTICANCER RESEARCH 24: 2515-2518 (2004) Table I. Characteristics of patients and controls. Table II. Pancreatic polypeptide (PP), carcinoembryonal antigen (CEA), neuron specific enolase (NSE) and prostate specific antigen (PSA) in Patients Controls p values patients and controls. Number 20 10 Diagnosis PP, CEA, NSE, PSA in males, Sex, m/f 13 /7 8/2 pmol/L microg/L microg/L microg/L Age, yrs 69.1±10.7 70.6±3.1 NS NSCLC 250 4.8 19 2.6 BMI, kg/m2 24.0±2.6 23.7±2.0 NS NSCLC 40 3.1 49 0.1 Performance status* 1.7±0.9 0.0±0.0 < 0.0001 NSCLC 398 0.7 5 0.8 Hb, g/L 12.1±1.7 14.8±0.8 < 0.001 NSCLC 72 7.9 7 2.5 Creatinin, mmol/L 81.1±24.2 83.1±11.6 NS NSCLC 332 0.7 6 0.8 Albumin, g/L 35.4±4.0 41.3±2.8 < 0.001 NSCLC 16 3.6 7 1.4 NSCLC 44 1.1 5 0.6 WHO, grades 0 – 4. NS = non significant, BMI = body mass index, NSCLC, Hb = hemoglobin. *Performance status: grade 0 = able to carry out adenocarcinoma 87 40.4 6 5.5 all normal activity without restriction; grade 1 = restricted in physically strenuous activity but ambulatory and able to carry out light work; NSCLC, grade 2 = ambulatory and capable of all self-care but unable to carry adenocarcinoma 31 140.1 21 out any work; up and about more than 50% of waking hours; grade 3 = capable of only limited self-care; confined to bed or chair more than NSCLC, 50% of waking hours; grade 4 = completely disabled; cannot carry out adenocarcinoma 12 2.3 5 any self-care; totally confined to bed or chair. SCLC 68 2.6 106 1.2 Ca. coli cum met. 151 7.1 10 2.9 Ca. coli cum met. 206 156.1 10 1.5 variation during deep breathing; immediate heart rate response to Ca. ventriculi cum met. 25 0.8 5 standing up; blood pressure response to standing up; and blood Ca. prostatae cum met. 28 2.5 6 397.4 pressure response to sustained handgrip. The tests were performed Ca. prostatae cum met. 126 0.9 16 20.1 in the same order in all subjects. Ca. mammae cum met. 37 1.2 7 Ca. mammae cum met. 160 14.1 10 Statistical analysis. Results are given as means±SD. At first the Ca. mammae cum met. 33 0.9 9 Student’s t-test for unpaired data was used to compare results between Malignt schwannom 23 0.5 5 the groups. Then, for selected tests we used analysis of variance Patients, mean±SD, (ANOVA) and the Mann-Whitney test when comparing test results n=20 107.0±111.4 19.6±44.9 15.7±23.5 31.3±105.5 between the groups. p<0.05 was considered statistically significant. Controls, mean±SD, Correlations between the tests and pulmonary function characteristics n=10 28.2±13.4 1.8±0.8 5.9±0.8 2.2±1.2 p, patients versus were performed using the Spearman’s rank correlation coefficient. controls < 0.05 NS NS NS Results Abbreviations: NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer Patient characteristics. Characteristics for patients and controls are given in Table I. The patients’ performance status was significantly reduced when compared to age-matched controls. Autonomic tests. The data are given in Table III. In individual According to the WHO performance status (grades 0-4), the autonomic tests, the patients had significantly decreased heart majority of patients were ambulatory and capable of self-care rate response to the Valsalva manoeuvre and blood pressure but unable to carry out any work. Haemoglobin and serum response to standing up compared to controls. The heart rate albumin were significantly decreased. Sex, age and body mass response to deep breathing and standing up, as well as the index (BMI) did not differ significantly between patients and blood pressure response to sustained handgrip, did not differ controls. The distribution regarding diagnoses was as follows: significantly between the groups. lung cancer 11 patients; squamous cell carcinoma 7, Correlations. There were no significant correlations between adenocarcinoma 3, small cell lung carcinoma 1, three breast patient characteristics, PP values, tumor markers and cancers, two prostate cancers, two colon cancers, one gastric autonomic tests in the patient group, and no significant cancer and one malignant schwannoma. All the patients had a difference in PP levels between lung cancer patients compared stage III-IV malignant disease. to patients with other malignant diseases. Biochemical markers. The patients’ PP levels were significantly Discussion higher than in the controls (p<0.05) (Table II). Tumor markers such as CEA, NSE and PSA (males) were In the present study, patients with advanced malignant disease not significantly increased in patients when compared to had a higher basal serum PP value than healthy controls. To controls (Table II). our knowledge, this finding has not been reported before. 2516 Hjalmarsen et al: Pancreatic Polypeptide in Advanced Malignant Disease Table III. Autonomic function in patients and controls. Cardiovascular testsa Patients, n=20 Controls, n=10 p values Heart rate response to Valsalva manoeuvre (ratio) 1.20±0.19 1.46±0.23 < 0.005 Heart rate response to deep breathing (ratio) 6.89±4.56 6.50±3.50 NS Heart rate response to standing up (ratio) 0.97±0.24 1.09±0.13 NS Blood pressure response to standing up (mmHg) -3.84±17.53 10.80±8.89 < 0.05 Blood pressure response to sustained handgrip (mmHg) 10.32±11.80 16.90±14.22 NS aHigher score = better performance When evaluated with tests for cardiovascular reflexes, References patients with advanced malignant disease demonstrated dysautonomia when compared with controls.
Load more

Recommended publications
  • A Comparative Survey of the RF-Amide Peptide Superfamily
    EDITORIAL published: 10 August 2015 doi: 10.3389/fendo.2015.00120 Editorial: A comparative survey of the RF-amide peptide superfamily Karine Rousseau 1*, Sylvie Dufour 1 and Hubert Vaudry 2 1 Laboratory of Biology of Aquatic Organisms and Ecosystems (BOREA), Muséum National d’Histoire Naturelle, CNRS 7208, IRD 207, Université Pierre and Marie Curie, UCBN, Paris, France, 2 Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM U982, International Associated Laboratory Samuel de Champlain, Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, Mont-Saint-Aignan, France Keywords: RF-amide peptides, receptors, evolution, functions, deuterostomes, protostomes The first member of the RF-amide peptide superfamily to be characterized, in 1977, was the cardioexcitatory peptide, FMRFamide, isolated from the ganglia of the clam Macrocallista nimbosa (1). Since then, a large number of such peptides, designated after their C-terminal arginine (R) and amidated phenylalanine (F) residues, have been identified in representative species of all major phyla. The discovery, 12 years ago, that the RF-amide peptide kisspeptin, acting via GPR54, was essential for the onset of puberty and reproduction, has been a major breakthrough in reproductive physiology (2–4). It has also put in front of the spotlights RF-amide peptides and has invigo- rated research on this superfamily of regulatory neuropeptides. The present Research Topic aims at illustrating major advances achieved, through comparative studies in (mammalian and non- mammalian) vertebrates and invertebrates, in the knowledge of RF-amide peptides in terms of evolutionary history and physiological significance. Since 2006, by means of phylogenetic analyses, the superfamily of RFamide peptides has been divided into five families/groups in vertebrates (5, 6): kisspeptin, 26RFa/QRFP, GnIH (including LPXRFa and RFRP), NPFF, and PrRP.
    [Show full text]
  • TRH-Like Peptides
    Physiol. Res. 60: 207-215, 2011 https://doi.org/10.33549/physiolres.932075 REVIEW TRH-Like Peptides R. BÍLEK1, M. BIČÍKOVÁ1, L. ŠAFAŘÍK2 1Institute of Endocrinology, Prague, Czech Republic, 2Urology Clinic, Beroun, Czech Republic Received September 6, 2010 Accepted October 8, 2010 On-line November 29, 2010 Summary of the leaders working in the area concerning the TRH TRH-like peptides are characterized by substitution of basic research was Professor V. Schreiber from Prague, Czech amino acid histidine (related to authentic TRH) with neutral or Republic, which already in 1959 formulated the acidic amino acid, like glutamic acid, phenylalanine, glutamine, hypothesis that adenohypophyseal acid phosphatase is tyrosine, leucin, valin, aspartic acid and asparagine. The related to thyrotropin secretion and that TRH is its presence of extrahypothalamic TRH-like peptides was reported in possible activator (Schreiber and Kmentova 1959, peripheral tissues including gastrointestinal tract, placenta, neural Schreiber et al. 1962). TRH precursor, human prepro- tissues, male reproductive system and certain endocrine tissues. TRH, consists of 242 amino acid residues, and contains Work deals with the biological function of TRH-like peptides in six separate copies of the TRH progenitor sequence different parts of organisms where various mechanisms may (Satoh and Mori 1994), which determine the primary serve for realisation of biological function of TRH-like peptides as structure of TRH as a tripeptide pyroglutamyl-histidinyl- negative feedback to the pituitary exerted by the TRH-like proline amide. The transcriptional unit of prepro-TRH is peptides, the role of pEEPam such as fertilization-promoting localized on chromosome 3 in humans (three exons peptide, the mechanism influencing the proliferative ability of interrupted by two introns) (Yamada et al.
    [Show full text]
  • Peptide Handbook a Guide to Peptide Design and Applications in Biomedical Research
    Peptide Handbook A Guide to Peptide Design and Applications in Biomedical Research First Edition www.GenScript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 USA Phone: 1-732-885-9188 Toll-Free: 1-877-436-7274 Fax: 1-732-885-5878 Table of Contents The Universe of Peptides Reliable Synthesis of High-Quality Peptides Molecular structure 3 by GenScript Characteristics 5 Categories and biological functions 8 Analytical methods 10 Application of Peptides Research in structural biology 12 Research in disease pathogenesis 12 Generating antibodies 13 FlexPeptideTM Peptide Synthesis Platform which takes advantage of the latest Vaccine development 14 peptide synthesis technologies generates a large capacity for the quick Drug discovery and development 15 synthesis of high-quality peptides in a variety of lengths, quantities, purities Immunotherapy 17 and modifications. Cell penetration-based applications 18 Anti-microorganisms applications 19 Total Quality Management System based on multiple rounds of MS and HPLC Tissue engineering and regenerative medicine 20 analyses during and after peptide synthesis ensures the synthesis of Cosmetics 21 high-quality peptides free of contaminants, and provides reports on peptide Food industry 21 solubility, quality and content. Synthesis of Peptides Diverse Delivery Options help customers plan their peptide-based research Chemical synthesis 23 according to their time schedule and with peace of mind. Microwave-assisted technology 24 ArgonShield™ Packing eliminates the experimental variation caused by Ligation technology 26 oxidization and deliquescence of custom peptides through an innovative Recombinant technology 28 Modifications packing and delivery technology. 28 Purification 30 Expert Support offered by Ph.D.-level scientists guides customers from Product identity and quality control 31 peptide design and synthesis to reconstitution and application.
    [Show full text]
  • Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide
    Effect of Atropine on Vagal Release of Gastrin and Pancreatic Polypeptide MARK FELDMAN, CHARLES T. RICHARDSON, IAN L. TAYLOR, and JOHN H. WALSH, Departments of Internal Medicine, Veterans Administration Hospital, Dallas, Texas 75216; University of California at Los Angeles Health Science Center, Los Angeles, California 90093; and The University of Texas Health Science Center at Dallas, Southwestern Medical School, Dallas, Texas 75235 A B S TRA C T We studied the effect of several doses of the rise in serum gastrin concentration induced by in- atropine on the serum gastrin and pancreatic poly- sulin hypoglycemia was further increased by atropine peptide responses to vagal stimulation in healthy premedication (1). In addition, several workers have human subjects. Vagal stimulation was induced by shown that atropine increases the serum gastrin con- sham feeding. To eliminate the effect of gastric acidity centration after an eaten meal (2-4). These observa- on gastrin release, gastric pH was held constant (pH 5) tions, together with the fact that basal and postprandial and acid secretion was measured by intragastric titra- gastrin levels rise after vagotomy (5-7), have led to tion. Although a small dose of atropine (2.3 ,ug/kg) speculation that the vagus nerve can inhibit, as well as significantly inhibited the acid secretory response and stimulate, gastrin release. completely abolished the pancreatic polypeptide re- For several reasons, however, none of these observa- sponse to sham feeding, this dose of atropine signifi- tions proves that the vagus nerve actually inhibits cantly enhanced the gastrin response. Higher atropine gastrin release under normal circumstances. First, doses (7.0 and 21.0,g/kg) had effects on gastrin and studies using insulin hypoglycemia as a vagal stimulant pancreatic polypeptide release which were similar to must be interpreted with caution because there is the 2.3-pAg/kg dose.
    [Show full text]
  • Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: a Pilot Dose-Ranging Study
    nutrients Article Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study Anne Christin Meyer-Gerspach 1,2,* , Jürgen Drewe 3, Wout Verbeure 4 , Carel W. le Roux 5, Ludmilla Dellatorre-Teixeira 5, Jens F. Rehfeld 6, Jens J. Holst 7 , Bolette Hartmann 7, Jan Tack 4, Ralph Peterli 8, Christoph Beglinger 1,2 and Bettina K. Wölnerhanssen 1,2,* 1 St. Clara Research Ltd. at St. Claraspital, 4002 Basel, Switzerland; [email protected] 2 Faculty of Medicine, University of Basel, 4001 Basel, Switzerland 3 Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 4001 Basel, Switzerland; [email protected] 4 Translational Research Center for Gastrointestinal Disorders, Catholic University of Leuven, 3000 Leuven, Belgium; [email protected] (W.V.); [email protected] (J.T.) 5 Diabetes Complications Research Centre, Conway Institute University College Dublin, 3444 Dublin, Ireland; [email protected] (C.W.l.R.); [email protected] (L.D.-T.) 6 Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark; [email protected] 7 Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark; [email protected] (J.J.H.); [email protected] (B.H.) 8 Department of Surgery, Clarunis, St. Claraspital, 4002 Basel, Switzerland; [email protected] * Correspondence: [email protected] (A.C.M.-G.); [email protected] (B.K.W.); Tel.: +41-61-685-85-85 (A.C.M.-G.
    [Show full text]
  • Identification of Neuropeptide Receptors Expressed By
    RESEARCH ARTICLE Identification of Neuropeptide Receptors Expressed by Melanin-Concentrating Hormone Neurons Gregory S. Parks,1,2 Lien Wang,1 Zhiwei Wang,1 and Olivier Civelli1,2,3* 1Department of Pharmacology, University of California Irvine, Irvine, California 92697 2Department of Developmental and Cell Biology, University of California Irvine, Irvine, California 92697 3Department of Pharmaceutical Sciences, University of California Irvine, Irvine, California 92697 ABSTRACT the MCH system or demonstrated high expression lev- Melanin-concentrating hormone (MCH) is a 19-amino- els in the LH and ZI, were tested to determine whether acid cyclic neuropeptide that acts in rodents via the they are expressed by MCH neurons. Overall, 11 neuro- MCH receptor 1 (MCHR1) to regulate a wide variety of peptide receptors were found to exhibit significant physiological functions. MCH is produced by a distinct colocalization with MCH neurons: nociceptin/orphanin population of neurons located in the lateral hypothala- FQ opioid receptor (NOP), MCHR1, both orexin recep- mus (LH) and zona incerta (ZI), but MCHR1 mRNA is tors (ORX), somatostatin receptors 1 and 2 (SSTR1, widely expressed throughout the brain. The physiologi- SSTR2), kisspeptin recepotor (KissR1), neurotensin cal responses and behaviors regulated by the MCH sys- receptor 1 (NTSR1), neuropeptide S receptor (NPSR), tem have been investigated, but less is known about cholecystokinin receptor A (CCKAR), and the j-opioid how MCH neurons are regulated. The effects of most receptor (KOR). Among these receptors, six have never classical neurotransmitters on MCH neurons have been before been linked to the MCH system. Surprisingly, studied, but those of most neuropeptides are poorly several receptors thought to regulate MCH neurons dis- understood.
    [Show full text]
  • What Is Pancreatic Polypeptide and What Does It Do?
    What is Pancreatic Polypeptide and what does it do? This document aims to evaluate current understanding of pancreatic polypeptide (PP), a gut hormone with several functions contributing towards the maintenance of energy balance. Successful regulation of energy homeostasis requires sophisticated bidirectional communication between the gastrointestinal tract and central nervous system (CNS; Williams et al. 2000). The coordinated release of numerous gastrointestinal hormones promotes optimal digestion and nutrient absorption (Chaudhri et al., 2008) whilst modulating appetite, meal termination, energy expenditure and metabolism (Suzuki, Jayasena & Bloom, 2011). The Discovery of a Peptide Kimmel et al. (1968) discovered PP whilst purifying insulin from chicken pancreas (Adrian et al., 1976). Subsequent to extraction of avian pancreatic polypeptide (aPP), mammalian homologues bovine (bPP), porcine (pPP), ovine (oPP) and human (hPP), were isolated by Lin and Chance (Kimmel, Hayden & Pollock, 1975). Following extensive observation, various features of this novel peptide witnessed its eventual classification as a hormone (Schwartz, 1983). Molecular Structure PP is a member of the NPY family including neuropeptide Y (NPY) and peptide YY (PYY; Holzer, Reichmann & Farzi, 2012). These biologically active peptides are characterized by a single chain of 36-amino acids and exhibit the same ‘PP-fold’ structure; a hair-pin U-shaped molecule (Suzuki et al., 2011). PP has a molecular weight of 4,240 Da and an isoelectric point between pH6 and 7 (Kimmel et al., 1975), thus carries no electrical charge at neutral pH. Synthesis Like many peptide hormones, PP is derived from a larger precursor of 10,432 Da (Leiter, Keutmann & Goodman, 1984). Isolation of a cDNA construct, synthesized from hPP mRNA, proposed that this precursor, pre-propancreatic polypeptide, comprised 95 residues (Boel et al., 1984) and is processed to produce three products (Leiter et al., 1985); PP, an icosapeptide containing 20-amino acids and a signal peptide (Boel et al., 1984).
    [Show full text]
  • Rfamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential
    Pharmaceuticals 2011, 4, 1248-1280; doi:10.3390/ph4091248 OPEN ACCESS Pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential Maria Findeisen †, Daniel Rathmann † and Annette G. Beck-Sickinger * Institute of Biochemistry, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany; E-Mails: [email protected] (M.F.); [email protected] (D.R.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-341-9736900; Fax: +49-341-9736909. Received: 29 August 2011; in revised form: 9 September 2011 / Accepted: 15 September 2011 / Published: 21 September 2011 Abstract: Different neuropeptides, all containing a common carboxy-terminal RFamide sequence, have been characterized as ligands of the RFamide peptide receptor family. Currently, five subgroups have been characterized with respect to their N-terminal sequence and hence cover a wide pattern of biological functions, like important neuroendocrine, behavioral, sensory and automatic functions. The RFamide peptide receptor family represents a multiligand/multireceptor system, as many ligands are recognized by several GPCR subtypes within one family. Multireceptor systems are often susceptible to cross-reactions, as their numerous ligands are frequently closely related. In this review we focus on recent results in the field of structure-activity studies as well as mutational exploration of crucial positions within this GPCR system. The review summarizes the reported peptide analogs and recently developed small molecule ligands (agonists and antagonists) to highlight the current understanding of the pharmacophoric elements, required for affinity and activity at the receptor family.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Inhibition of Gastrin-Releasing Peptide Attenuates Phosphate-Induced Vascular Calcification
    cells Article Inhibition of Gastrin-Releasing Peptide Attenuates Phosphate-Induced Vascular Calcification Hyun-Joo Park 1,2, Yeon Kim 1,2, Mi-Kyoung Kim 1, Jae Joon Hwang 3, Hyung Joon Kim 1,2 , Soo-Kyung Bae 2,4 and Moon-Kyoung Bae 1,2,* 1 Department of Oral Physiology, BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan 50610, Korea; [email protected] (H.-J.P.); [email protected] (Y.K.); [email protected] (M.-K.K.); [email protected] (H.J.K) 2 Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan 50610, Korea; [email protected] 3 Department of Oral and Maxillofacial Radiology, School of Dentistry, Pusan National University, Dental Research Institute, Yangsan 50610, Korea; [email protected] 4 Department of Dental Pharmacology, BK21 PLUS Project, School of Dentistry, Pusan National University, Yangsan 50610, Korea * Correspondence: [email protected]; Tel.: +82-51-510-8239 Received: 29 January 2020; Accepted: 13 March 2020; Published: 17 March 2020 Abstract: Vascular calcification is the pathological deposition of calcium/phosphate in the vascular system and is closely associated with cardiovascular morbidity and mortality. Here, we investigated the role of gastrin-releasing peptide (GRP) in phosphate-induced vascular calcification and its potential regulatory mechanism. We found that the silencing of GRP gene and treatment with the GRP receptor antagonist, RC-3095, attenuated the inorganic phosphate-induced calcification of vascular smooth muscle cells (VSMCs). This attenuation was caused by inhibiting phenotype change, apoptosis and matrix vesicle release in VSMCs. Moreover, the treatment with RC-3095 effectively ameliorated phosphate-induced calcium deposition in rat aortas ex vivo and aortas of chronic kidney disease in mice in vivo.
    [Show full text]
  • Monoclonal Antibody to Adrenocorticotropic Hormone (ACTH) (1-24) - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AM50155PU-N Monoclonal Antibody to Adrenocorticotropic Hormone (ACTH) (1-24) - Purified Alternate names: Adrenocorticotropic hormone, Corticotropin, POMC Quantity: 0.2 mg Concentration: 0.2 mg/ml Background: ACTH (Adrenocorticotrophic hormone) is produced and secreted by the anterior pituitary gland, and is a key component of the hypothalamic-pituitary-adrenal axis. ACTH is synthesized from the precursor molecule pre-opiomelanocorin (POMC). POMC undergoes proteolytic cleavages and processing to generate not only ACTH but also a number of other small biologically active peptides including alpha-MSH and beta- endorphin, all in cell type specific manners. The production of ACTH is triggered by biological stress. ACTH, in turn, then stimulates the secretion of corticosteroids by the adrenal cortex. The half-life of ACTH in human blood is only about ten minutes. An excess of ACTH can cause Cushing's syndrome whereas ACTH deficiency can result in secondary adrenal insufficiency. ACTH consists of 39 amino acids (aa), and can be proteolytically cleaved into different active fragments including CLIP (corticotropin-like intermediate lobe peptide), consisting of aa 17-39, which stimulates insulin production. Synacthen is an active synthetic form of ACTH, corresponding to the first 24 aa, which is used to conduct ACTH stimulation tests. Uniprot ID: P01189 NCBI: 9606 GeneID: 5443 Host / Isotype: Mouse / IgG1 Recommended Isotype SM10P (for use in human samples), SM20P (for use in rat samples), AM03095PU-N Controls: Clone: SPM333 Immunogen: Synthetic peptide corresponding to aa1-24 of human ACTH.
    [Show full text]
  • REVIEW the Role of Rfamide Peptides in Feeding
    3 REVIEW The role of RFamide peptides in feeding David A Bechtold and Simon M Luckman Faculty of Life Sciences, University of Manchester, 1.124 Stopford Building, Oxford Road, Manchester M13 9PT, UK (Requests for offprints should be addressed to D A Bechtold; Email: [email protected]) Abstract In the three decades since FMRFamide was isolated from the evolution. Even so, questions remain as to whether feeding- clam Macrocallista nimbosa, the list of RFamide peptides has related actions represent a primary function of the RFamides, been steadily growing. These peptides occur widely across the especially within mammals. However, as we will discuss here, animal kingdom, including five groups of RFamide peptides the study of RFamide function is rapidly expanding and with identified in mammals. Although there is tremendous it so is our understanding of how these peptides can influence diversity in structure and biological activity in the RFamides, food intake directly as well as related aspects of feeding the involvement of these peptides in the regulation of energy behaviour and energy expenditure. balance and feeding behaviour appears consistently through Journal of Endocrinology (2007) 192, 3–15 Introduction co-localised with classical neurotransmitters, including acetyl- choline, serotonin and gamma-amino bulyric acid (GABA). The first recognised member of the RFamide neuropeptide Although a role for RFamides in feeding behaviour was family was the cardioexcitatory peptide, FMRFamide, first suggested over 20 years ago, when FMRFamide was isolated from ganglia of the clam Macrocallista nimbosa (Price shown to be anorexigenic in mice (Kavaliers et al. 1985), the & Greenberg 1977). Since then a large number of these question of whether regulating food intake represents a peptides, defined by their carboxy-terminal arginine (R) and primary function of RFamide signalling remains.
    [Show full text]